BioLineRx (BLRX) trades 22% higher before the bell.
Investors appear pleased with early results from a Phase 2 study of BL-8040 in AML.
Summary: BL-8040 (alone and in combination with Ara-C) is safe at the tested doses, triggers substantial mobilization of cancer cells from the bone marrow to the peripheral blood (the idea being to make them more susceptible to chemo), and, at higher doses, appears to have contributed to cancer cell death.
CEO Kinneret Savitsky is "very excited." (PR)